(0.23%) 5 111.44 points
(0.19%) 38 312 points
(0.23%) 15 965 points
(-1.34%) $82.73
(3.90%) $1.998
(0.04%) $2 348.10
(-0.12%) $27.50
(3.60%) $955.25
(-0.20%) $0.933
(-0.33%) $10.99
(-0.44%) $0.797
(1.71%) $93.44
@ $8.00
発行日: 14 2月 2024 @ 23:30
リターン: 10.50%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 4.30 %
Live Chart Being Loaded With Signals
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy...
Stats | |
---|---|
本日の出来高 | 28 545.00 |
平均出来高 | 267 917 |
時価総額 | 333.77M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-0.570 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.830 |
ATR14 | $0.0370 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smith Ian F | Buy | 3 256 | Common Stock |
2024-04-03 | Smith Ian F | Sell | 3 256 | Restricted Stock Units |
2024-02-13 | Hanrahan Jessie | Buy | 65 000 | Employee Stock Option (Right to Buy) |
2024-02-13 | Hanrahan Jessie | Buy | 32 500 | Restricted Stock Units |
2024-02-13 | Cumbo Alexander | Buy | 240 250 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
95.48 |
Last 96 transactions |
Buy: 8 088 873 | Sell: 207 617 |
ボリューム 相関
Solid Biosciences Inc 相関 - 通貨/商品
Solid Biosciences Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-2.58M (0.00 %) |
EPS: | $-4.83 |
FY | 2023 |
収益: | $0 |
総利益: | $-2.58M (0.00 %) |
EPS: | $-4.83 |
FY | 2022 |
収益: | $8.09M |
総利益: | $5.69M (70.25 %) |
EPS: | $-7.70 |
FY | 2021 |
収益: | $13.62M |
総利益: | $0.00 (0.00 %) |
EPS: | $-10.14 |
Financial Reports:
No articles found.
Solid Biosciences Inc
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。